Madrigal Pharma (MDGL) Tops Q2 EPS by $1.73, Beats on Revenue

Madrigal Pharma (NASDAQ: MDGL) reported Q2 EPS of ($1.90), $1.73 better than the analyst estimate of ($3.63). Revenue for the quarter came in at $212.8 million versus the consensus estimate of $159.45 million.

For earnings history and earnings-related data on Madrigal Pharma (MDGL) click here.

You May Also Be Interested In

• Trump on Iran: we're trying to work out a deal that's fair
• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• William Blair Upgrades Backblaze Inc (BLZE) to Market Perform